Important turnout for the 2022 edition of ENDOLIVE, held in Rome on 30, 31 March and 1 April, organized by Professor Guido Costamagna, full professor of General Surgery at the Catholic University and director of the Operative Unit of Digestive Surgical Endoscopy of the University Polyclinic Agostino Gemelli Irccs.
The great protagonist of this edition was certainly Artificial Intelligence applied to the early diagnosis of colorectal cancers: in fact, alongside the work of the endoscopist, it helps to improve diagnosis performance and the recognition of anomalies.
Colorectal cancer accounts for 10 percent of all cancers diagnosed worldwide, and is third in incidence after female breast (11.7 percent) and lung (11.4 percent) cancer. In Italy, the most recent estimates speak of over 43,700 new cases per year: about 20,282 in women and 23,420 in men. Given the incidence of this type of cancer, an early diagnosis is essential, which allows you to intervene as soon as possible. Today the most used examination for the diagnosis of colorectal cancer is colonoscopy but, in the short term, cutting-edge, less invasive but, above all, highly performing tools may be available.
Precisely in this perspective of innovation and revolution in the diagnosis of colorectal cancer, during the workshop “How artificial intelligence is revolutionizing capsule enteroscopy” held by Prof. Cristiano Spada and Prof. Cesare Hassan, the advantages of ” Artificial Intelligence applied to the video capsule, with a particular focus on the new video capsule for the small intestine NAVICAM SB System.
This system, according to the study published in the journal Gastroenterology, “Gastroenterlogist-Level identification of small-bowel diseases and normal variants by capsule endoscopy using a deep learning model”, is able to identify anomalies with a sensitivity of 99.88% in analysis per patient and 99.90% in the analysis by lesion, compared to the conventional analysis.
Concrete results that create new and encouraging perspectives in the prevention of a disease which, if diagnosed at stage I, has a survival rate of over 90%.